Iambic Therapeutics, Inc. priced its initial public offering at $16.00 a share, offering 9,375,000 shares of common stock, to list on the Nasdaq Global Select Market under the symbol IAM. It filed a Form S-1 registration statement for an initial public offering on September 21, 2026. As of November 6, 2026, its final prospectus is on file (Form 424B4, October 15, 2026).
Sell to companies like Iambic Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Iambic Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-09-21. It has amended it 1 time. It filed its final prospectus on 2026-10-15, at a public offering price of $16.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Iambic Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 9, 2026 | Form D, private offering | $65.97M sold | Form D page | Source |
| April 8, 2026 | Form D, private offering | $27.77M sold | Form D page | Source |
| November 21, 2025 | Form D, private offering | $99.27M sold | Form D page | Source |
Check before you invest in Iambic Therapeutics, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Iambic Therapeutics, Inc. and the records around it.
The people at Iambic Therapeutics, Inc.
- William Rastetter is also named on 6 other Form D filings: Dare Bioscience, Inc. (Aug 2026)
Iambic Therapeutics, Inc. elsewhere on the record
- Company profile and every filing Sep 2026
- Form D filing Sep 2026
- Form D filing Apr 2026
- Who owns it
Companies that share a holder
- Qatar Investment Authority also filed stake reports on 11 other companies: Aspen Neuroscience, Inc. (Nov 2026), Global Business Travel Group, Inc. (Sep 2026), Nanobiotix SA (Jul 2026)
Also filing to list on the Nasdaq Global Select Market
IPO filings on the Nasdaq Global Select Market in Q4 2026, newest first.
- Anthropic, PBC (Nov 2026)
Watch Iambic Therapeutics, Inc.
Get an email when Iambic Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Iambic Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Iambic Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Iambic Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “IAM.”From the 424B4 filed 2026-10-15
Shares offered
This is an initial public offering of shares of common stock of Iambic Therapeutics, Inc. We are offering 9,375,000 shares of common stock to be sold in this offering.From the 424B4 filed 2026-10-15
Offering price
The initial public offering price is $16.00 per share.From the 424B4 filed 2026-10-15
Use of proceeds
We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to advance the clinical development of IAM1363 through the completion of our ongoing Phase 1 trial, the initiation of one or more Phase 2 trials intended to support potential applications for accelerated approval, subject to FDA feedback, and the initiation of a Phase 3 trial intended to support a potential application for full approval; to advance the clinical development of IAM217, including the initiation and advancement of a Phase 1/2 clinical trial through the completion of the Phase 1 dose escalation portion of the trial; to advance the clinical development of IAM-C1,…From the 424B4 filed 2026-10-15
Net loss or income
37,736,676 (1) The pro forma basic and diluted net loss per share for the year ended December 31, 2025, and for the six months ended June 30, 2026, have been computed to give effect to (a) the automatic conversion of all outstanding shares of our convertible preferred stock into shares of common stock as of such date, and (b) the Notes Conversion at the assumed initial public offering price of $16.00 per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, as if the shares resulting from the Notes Conversion were outstanding as of such date.From the S-1/A filed 2026-10-08
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-09-21 | Registration statement filed | S-1 |
| 2026-10-08 | Registration statement amended | S-1/A |
| 2026-10-15 | Final prospectus filed: the offering is priced | 424B4 |
Iambic Therapeutics, Inc.'s full funding historyFounders and team
Tools for this story
Each opens in a new tab, filled in for Iambic Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.